November 24, 2016 - By Louis Casey · 0 Comments
The stock of ANTRIABIO INCORPORATED (OTCMKTS:ANTB) registered a decrease of 3.49% in short interest. ANTB’s total short interest was 265,100 shares in November as published by FINRA. Its down 3.49% from 274,700 shares, reported previously. With 18,700 shares average volume, it will take short sellers 14 days to cover their ANTB’s short positions. The stock closed at $1.4 during the last session. It is down 35.92% since April 22, 2016 and is uptrending. It has outperformed by 30.51% the S&P500.
AntriaBio, Inc. is a biopharmaceutical company. The company has a market cap of $57.33 million. The Firm develops sustained release injectable therapies. It currently has negative earnings. The Company’s products include AB101 and AB301.
AntriaBio, Inc., incorporated on January 2, 2013, is a biopharmaceutical company. The Firm develops sustained release injectable therapies. The Company’s products include AB101 and AB301.
More notable recent AntriaBio Inc (OTCMKTS:ANTB) news were published by: Streetinsider.com which released: “Form 8-K AntriaBio, Inc. For: Jun 06” on June 08, 2015, also Seekingalpha.com with their article: “AntriaBio Presents Vast Upside With Disruptive Once-Weekly Insulin” published on July 16, 2014, Marketwatch.com published: “AntriaBio Announces $12 Million Private Placement” on June 29, 2016. More interesting news about AntriaBio Inc (OTCMKTS:ANTB) were released by: Seekingalpha.com and their article: “Preclinical Data At ADA Supports Development Of AntriaBio’s AB101 (ANTB)” published on June 11, 2015 as well as Bizjournals.com‘s news article titled: “As potential once-a-week insulin advances, AntriaBio eliminates a $44M obligation” with publication date: November 11, 2014.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey